The Company


Research & Development

Product Candidates
Investor Relations
Contact Us



Randal J. Kirk - Founder, Chairman of the Board, President & Chief Executive Officer

Randal J. Kirk

Mr. Kirk is our founder and has served as a director since August 1996, as Chairman of the Board since 1996 and as President and Chief Executive Officer since October 2001. Mr. Kirk has over 20 years of experience in the health-care industry. Previously, Mr. Kirk co-founded General Injectables & Vaccines, Inc., a pharmaceutical distributor (GIV), in 1983 and served as Chairman of the board of GIV prior to the sale of that company in 1998. Mr. Kirk served as a member of the board of directors of Scios, Inc. (previously traded on NASDAQ and recently acquired by Johnson & Johnson) between February 2000 and May 2002.

Mr. Kirk also currently serves as Senior Managing Director of Third Security, LLC, an investment management firm founded by Mr. Kirk, since March 1999, as a member of the board of directors of Clinical Data, Inc. (NASDAQ: CLDA) since September 2002, and as chairman of its board since December, 2004. He has served on the board of directors of the Radford University Foundation, Inc. since September 1998 the Virginia Bioinformatics Institute Policy Advisory Board since March 2004, and the Board of Visitors of Radford University since July 2003. He serves as well on a number of other foundations. Mr. Kirk received a B.A. in Business from Radford University and a J.D. from the University of Virginia.

Krish S. Krishnan - Chief Operating Officer and Chief Financial Officer

Mr. Krishnan has served as a member of our board of directors since March 2003 and as Chief Financial Officer and Chief Operating Officer since April 2004. He served as President and CEO of Harvest Pharmaceuticals Inc. between February 2003 and April 2004. Since March 2002, Mr. Krishnan served as a Senior Managing Director of Third Security, LLC. Previously, Mr. Krishnan was a director at a start-up venture,, Inc., which was sold to Ariba Technologies Inc., in August 2000. He then served as a managing principal of Ariba, focusing primarily in the pharmaceutical industry, until joining Third Security, LLC in March 2002. Mr. Krishnan was also a senior manager with A.T. Kearney, Inc., a management consulting firm, where he advised pharmaceutical companies on strategic and operational issues; a consultant with KPMG Peat Marwick; and an engineer with E.I. Dupont de Nemours, a multinational chemical company. Mr. Krishnan received a B.S. in Mechanical Engineering from the Indian Institute of Technology (IIT), a M.S. in Engineering from the University of Toledo, and an M.B.A. from The Wharton School at the University of Pennsylvania.

Garen Z. Manvelian, M.D. - Chief Medical Officer, Vice President Clinical and Regulatory Affairs

Dr. Manvelian came to New River in October 2006 from SkyePharma Inc., where he served since 2000 as Senior Director, Clinical and Medical Affairs. Prior to that, he served as a Clinical Research Scientist at Quintiles CNS Therapeutics.

Dr. Manvelian holds an M.D. degree from the Vitebsk State Medical Institute in Vitebsk, Belarus. He completed a residency program in anesthesiology at the Republic Hospital of Armenia in Yerevan, Armenia, and a postdoctoral fellowship at the Yale University School of Medicine Department of Anesthesiology

John K. Thottathil, Ph.D. - Chief Scientific Officer

John K. Thottathil

New River Pharmaceuticals Inc. welcomed Dr. Thottathil as its Chief Scientific Officer in April, 2006. Prior to joining New River, Dr. Thottathil served for over four years as the Director of Core Research and Development Chemistry, Diagnostic Division, at Abbott Laboratories. Prior to that, he worked at Bristol-Myers Squibb for 19 years in a variety of positions, most recently as Director of Outsourcing, Worldwide Process Research and Development, and earlier as Director of Chemical Process Research Departments in New Brunswick, NJ and Candiac, Canada. Several of his projects resulted in product launches; he has contributed to 60 patents, and has authored or co-authored more than 40 peer-reviewed publications.

He holds a Doctor of Philosophy degree in Organic Chemistry from the Indian Institute of Science in Bangalore, India, and conducted post-doctoral research at Yale University in New Haven, Connecticut, and Emory University in Atlanta, Georgia.

Suma M. Krishnan - Vice President, Product Development

Mrs. Krishnan has 14 years experience in drug development. Mrs. Krishnan has been Vice President, Product Development at New River Pharmaceuticals Inc. since September 2002. Prior to joining New River Pharmaceuticals, Mrs. Krishnan served in the following capacities: Director, Regulatory Affairs at Shire Pharmaceuticals, Inc., a specialty pharmaceutical company; Senior Project Manager at Pfizer, Inc., a multi-national pharmaceutical company; and a consultant at the Weinberg Group, a pharmaceutical and environmental consulting firm. Mrs. Krishnan began her career as a discovery scientist for Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, a multi-national pharmaceutical company, in May 1991. Mrs. Krishnan received a M.S. in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research ( India ) and an undergraduate degree in Organic Chemistry from Ferguson University ( India ).

Samir D. Roy, Ph.D. – Vice President, Formulation and Manufacturing

Dr. Roy joined the New River Pharmaceuticals Inc. team as its Vice President, Formulation and Manufacturing in August, 2006. Immediately prior to joining New River, Dr. Roy served as the Executive Director of Product Research at Watson Pharmaceuticals Inc. In his nearly twenty years in the pharmaceutical industry, he has held positions with Insite Vision Inc., Pfizer-Agouron Pharmaceutical Inc., Roche Pharmaceuticals, and Cygnus Therapeutics Inc. He has authored or co-authored more than 25 journal articles, is listed on ten U.S. patents, and has been involved in the development of a number of FDA product approvals.

Dr. Roy holds a Ph.D. degree from the College of Pharmacy, University of Saskatchewan in Saskatoon, Canada, with a research focus on the oral absorption of amphetamines and its analogs: drug metabolism, bioanalytical method development and PK modeling. He conducted a post-doctoral fellowship at the University of Michigan College of Pharmacy in Ann Arbor, Michigan, with a research focus on physicochemical characterizations of narcotic analgesics, skin transport mechanism, transdermal formulations for preclinical/clinical trials. He also holds a B.S. degree in Pharmacy from the BHU Institute of Technology, India.

Clifton R. Herndon II - Vice President, Finance and Controller

Clifton R. Herndon

Mr. Herndon has served as our Controller since May 1999 and was recently elected as Vice President, Finance. He also has served as a Managing Director with Third Security, LLC, an investment management firm, since September 1999. Previously, Mr. Herndon served as the Director of Financial Operations for Biological & Popular Culture, Inc., an affiliate; as Assistant Controller for General Injectables & Vaccines, Inc., a pharmaceutical distributor, from November 1997 through December 31, 1998; as Assistant Controller and Cost Accounting Manager with Long-Airdox Company, a manufacturer of mining equipment, from May 1996 to November 1997; and as a Manager with Ernst & Young, LLP from October 1994 to May 1996. Mr. Herndon began his career with Ernst & Young, LLP in July 1989. Mr. Herndon received a B.B.A. in Accounting from Marshall University.

Board of Directors

The Company|Management|Research & Development|Product Candidates|Investor Relations|Contact Us

© 2004 New River Pharmaceuticals Inc.